Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN 203818 in Irritable Bowel Syndrome Pain
NCT00441766Phase 2Terminated
- Sponsor
- Allergan
- Start
- Mar 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rezatomidine in irritable bowel syndrome (IBS) (4 arms), sponsored by Allergan. Primary endpoint: Mean Highest-Average-Pain at 4 weeks. Started Mar 2007; status: terminated.
02
Drugs
rezatomidine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT00441766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00441766.